Stem cells in subclinical hypothyroidism

Not Applicable

Completed

• Conditions: Hypothyroidism; Nutritional, Metabolic, Endocrine; Other hypothyroidism

• Registration Number: ISRCTN70334066
• Lead Sponsor: Gateshead Health NHS Foundation Trust (UK)

Brief Summary

2010 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19897678 results 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35923624/ subclinical thyrotoxicosis and cardiovascular risk results (added 05/08/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-09-16
• Study Completion: 2009-11-30
• Last Update Posted: 15 August 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Both males and females, age less than 70
2. Patients with confirmed subclinical hypothyroidism (thyroid-stimulating hormone [TSH]<10 mU/L) and overt hypothyroidism (TSH>10 mU/L)

Exclusion Criteria

1. Treatment for thyroid conditions
2. Known cardiovascular disease or risk factors

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Number and function of endothelial progenitor cells.<br><br> All outcomes will be assessed before and after thyroxine therapy (being stable for 3 months on therapy).<br>

Secondary Outcome Measures

Name	Time	Method
<br> Flow mediated dilatation.<br><br> All outcomes will be assessed before and after thyroxine therapy (being stable for 3 months on therapy).<br>